Growth hormone given to two children during targeted tumor treatment
Original title: Case Report: Case series: growth hormone replacement for severe growth hormone deficiency during BRAF inhibitor therapy in pediatric low-grade glioma: long-term follow-up.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is a report on only two children, not a trial that can show safety.
The short version
Two children took growth hormone while on a tumor drug, and no tumor growth was found.
What was studied. Doctors report on two children with a slow-growing brain tumor near the pituitary gland. Both had a severe lack of growth hormone. Both were given growth hormone while still taking vemurafenib, a targeted tumor drug.
What they found. The growth hormone dose was adjusted over two months, with regular blood tests and close checks. Over about six years on both treatments, growth held steady and blood fat levels got better. Catch-up growth stayed limited and the bone results were mixed. No tumor growth and no new cancers were found during the follow-up.
What this means, and what it doesn't
What it could mean: This adds to the small amount known about giving growth hormone during this tumor drug. A care team might weigh it for a child who needs it, with close monitoring. Families should ask their own team about the risks, since safety data for this mix is still missing.
What it doesn't mean: This does not show that growth hormone is safe or helpful during this tumor drug. It is a report on just two children, not a trial, so it cannot answer the safety question. The authors say larger studies are needed to know who might benefit. It is not a treatment for the tumor itself, and it is not a promise of a cure.
Source: PubMed, October 8, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.